

EVALUATION OF THE SURVIVAL TIME OF A0-90 CLINICAL TRIAL FOR PROGRESSIVE OR RECURRENT GASTRIC CANCER

Narihida Goseki et al.

A Phase II clinical trial using A0-90 TPN and MF (mitomycin C and 5-fluorouracil) therapy for progressive or recurrent gastric cancer was performed by 53 collaborating institutions. We reported antitumor efficacy and safety of this therapy in the 32nd Congress of the Japanese Society for Cancer Therapy, and in the 33rd we reported the results of evaluation of quality of life during this therapy. By using methionine-free A0-90 TPN, we can increase antitumor efficacy without an increase in toxicity. We report here the efficacy of A0-90 and MF on survival of gastric cancer patients (recurrent after surgery with measurable regions). In this clinical trial, patients were randomly assigned to four groups: (1) 5-FU 350mg/m²/day, iv, day 1-14, (2) MMC 7 mg/m², iv, days 7 and 14, (3) A0-90 TPN 500-750 ml/day (AO/MF group), and (4) the control amino acid TPN 600-800 ml/day, (C/MF group). TPN was administered for two weeks. AO/MF significantly prolonged survival time compared to the C/MF group (AO/MF, 221 days vs. C/MF, 118 days; 50% MST; P=0.004, Log-Rank test). In conclusion, by using AO-90 and MF therapy, we can prolong the survival time for the gastric cancer patient with liver metastasis or lymph node metastasis, demonstrating the antitumor efficacy of methionine-depleted TPN.

TABLE 1
SURVIVAL EFFICACY OF METHIONINE-DEPLETED TPN

	<u>Treatment</u>	
	<u>C/MF</u>	<u>AO/MF</u>
Mean Survival Time	118 days	221 days

J. Jpn. Soc. For Cancer Ther., Vol. XXXI, No. 8, 20 September 1996, p. 610 (172).